Who
James Basta
EVP, General Counsel
Company insider
Files Form 4 as: EVP, General Counsel, Intellia Therapeutics; Chief Legal Officer, Kura Oncology.
In numbers
- Trades disclosed
- 29
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $612K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 4 Nov 2019
- Last trade
- 2 Mar 2026
- Last filed
- 3 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Mar 2026filed 3 Mar 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $17K1,211 at $13.78 | filing |
| 2 Mar 2026filed 3 Mar 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $17K1,211 at $13.78 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —46,080 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —65,829 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —65,829 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —46,080 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $96K10,397 at $9.21 | filing |
| 5 Jan 2026filed 7 Jan 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $96K10,397 at $9.21 | filing |
| 4 Mar 2025filed 4 Mar 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $23K2,572 at $8.99 | filing |
| 1 Mar 2025filed 4 Mar 2025 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —57,143 at $0.00 | filing |
| 1 Mar 2025filed 4 Mar 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $86K7,074 at $12.18 | filing |
| 4 Mar 2024filed 5 Mar 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $76K2,297 at $32.99 | filing |
| 1 Mar 2024filed 5 Mar 2024 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —46,752 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —32,394 at $0.00 | filing |
| 3 Jan 2024filed 5 Jan 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $112K3,805 at $29.46 | filing |
| 2 Mar 2023filed 3 Mar 2023 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $48K1,088 at $43.88 | filing |
| 1 Mar 2023filed 3 Mar 2023 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —34,674 at $0.00 | filing |
| 1 Mar 2023filed 3 Mar 2023 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —24,539 at $0.00 | filing |
| 1 Mar 2023filed 3 Mar 2023 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —12,269 at $0.00 | filing |
News
Contrasting Intellia Therapeutics (NASDAQ:NTLA) and BeyondSpring (NASDAQ:BYSI)NTLA · tickerreport.com · 19 Oct 2026Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)NTLA · themarketsdaily.com · 19 Oct 2026Intellia Therapeutics Names New CMO To Oversee Clinical And Regulatory FunctionsNTLA · rttnews.com · 13 Oct 2026
0 headlines in the last 90 days name James Basta; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.